Anti-NFkB p100 / p52 antibody (ab6549)


  • Product nameAnti-NFkB p100 / p52 antibody
    See all NFkB p100 / p52 primary antibodies
  • Description
    Rabbit polyclonal to NFkB p100 / p52
  • Tested applicationsSuitable for: WB, IP, ELISAmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Human NFkB p52/p100 peptide corresponding to a region near the N-terminus of the human protein conjugated to Keyhole Limpet Hemocyanin (KLH).



Our Abpromise guarantee covers the use of ab6549 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
  • Application notesELISA: Use at an assay dependent dilution.
    IP: Use at an assay dependent dilution.
    WB: 1/1000. Predicted molecular weight: 52 kDa.
    Use control peptide at 1µl per µl of antiserum

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionNF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65.
    • Involvement in diseaseNote=A chromosomal aberration involving NFKB2 is found in a case of B-cell non Hodgkin lymphoma (B-NHL). Translocation t(10;14)(q24;q32) with IGHA1. The resulting oncogene is also called Lyt-10C alpha variant.
      Note=A chromosomal aberration involving NFKB2 is found in a cutaneous T-cell leukemia (C-TCL) cell line. This rearrangement produces the p80HT gene which encodes for a truncated 80 kDa protein (p80HT).
      Note=In B-cell leukemia (B-CLL) cell line, LB40 and EB308, can be found after heterogeneous chromosomal aberrations, such as internal deletions.
    • Sequence similaritiesContains 7 ANK repeats.
      Contains 1 death domain.
      Contains 1 RHD (Rel-like) domain.
    • DomainThe C-terminus of p100 might be involved in cytoplasmic retention, inhibition of DNA-binding by p52 homodimers, and/or transcription activation.
      The glycine-rich region (GRR) appears to be a critical element in the generation of p52.
    • Post-translational
      While translation occurs, the particular unfolded structure after the GRR repeat promotes the generation of p52 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like), being able to form cytosolic complexes with NF-kappa B, trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.
      Subsequent to MAP3K14-dependent serine phosphorylation, p100 polyubiquitination occurs then triggering its proteasome-dependent processing.
      Constitutive processing is tightly suppressed by its C-terminal processing inhibitory domain, named PID, which contains the death domain.
    • Cellular localizationNucleus. Cytoplasm. Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor.
    • Information by UniProt
    • Database links
    • Alternative names
      • CVID10 antibody
      • DNA binding factor KBF2 antibody
      • DNA-binding factor KBF2 antibody
      • H2TF1 antibody
      • Lymphocyte translocation chromosome 10 antibody
      • Lymphocyte translocation chromosome 10 protein antibody
      • Lyt 10 antibody
      • Lyt10 antibody
      • NF kB2 antibody
      • NFKB2 antibody
      • NFKB2_HUMAN antibody
      • Nuclear factor NF kappa B p100 subunit antibody
      • Nuclear factor NF kappa B p52 subunit antibody
      • Nuclear factor NF-kappa-B p52 subunit antibody
      • Nuclear factor of kappa light chain gene enhancer in B cells 2 antibody
      • Nuclear factor of kappa light polypeptide gene enhancer in B cells 2 antibody
      • Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 antibody
      • Oncogene Lyt 10 antibody
      • Oncogene Lyt-10 antibody
      • p105 antibody
      • p49/p100 antibody
      see all

    References for Anti-NFkB p100 / p52 antibody (ab6549)

    ab6549 has not yet been referenced specifically in any publications.

    Product Wall

    The immunogen we used to make this antibody is Human NFKB2 p52/p100 peptide corresponding to aa residue 1-19 the human protein conjugated to Keyhole Limpet Hemocyanin (KLH).

    This antibody does recognize the p100 precursor on Western blots. We haven't tested it in a super shift assay.

    The sequence of the peptide for ab6549 is: MES CYN PGL DGI IEY DDF K

    This antibody has not been tested for cross-reactivity against the mouse antigen. Unfortunately, we do not have any free samples of this antibody available at present. The best suggestion to predict likely cross-reactivity is to check for high sequence...

    Read More

    The answer to both questions is no.